Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding

2001 ◽  
Vol 358 (1) ◽  
pp. 185-192 ◽  
Author(s):  
Susan PANG ◽  
Anthony J. CHUBB ◽  
Sylva L. U. SCHWAGER ◽  
Mario R. W. EHLERS ◽  
Edward D. STURROCK ◽  
...  

Angiotensin-converting enzyme (ACE) is one of a growing number of integral membrane proteins that is shed from the cell surface through proteolytic cleavage by a secretase. To investigate the requirements for ectodomain shedding, we replaced the glycosylphosphatidylinositol addition sequence in membrane dipeptidase (MDP) - a membrane protein that is not shed - with the juxtamembrane stalk, transmembrane (TM) and cytosolic domains of ACE. The resulting construct, MDP–STMACE, was targeted to the cell surface in a glycosylated and enzymically active form, and was shed into the medium. The site of cleavage in MDP–STMACE was identified by MS as the Arg374-Ser375 bond, corresponding to the Arg1203-Ser1204 secretase cleavage site in somatic ACE. The release of MDP–STMACE and ACE from the cells was inhibited in an identical manner by batimastat and two other hydroxamic acid-based zinc metallosecretase inhibitors. In contrast, a construct lacking the juxtamembrane stalk, MDP–TMACE, although expressed at the cell surface in an enzymically active form, was not shed, implying that the juxtamembrane stalk is the critical determinant of shedding. However, an additional construct, ACEΔC, in which the N-terminal domain of somatic ACE was fused to the stalk, TM and cytosolic domains, was also not shed, despite the presence of a cleavable stalk, implying that in contrast with the C-terminal domain, the N-terminal domain lacks a signal required for shedding. These data are discussed in the context of two classes of secretases that differ in their requirements for recognition of substrate proteins.

Biochemistry ◽  
2003 ◽  
Vol 42 (23) ◽  
pp. 6965-6976 ◽  
Author(s):  
Olga A. Kost ◽  
Irina V. Balyasnikova ◽  
Elena E. Chemodanova ◽  
Irina I. Nikolskaya ◽  
Ronald F. Albrecht ◽  
...  

2005 ◽  
Vol 4 (2) ◽  
pp. 258-267 ◽  
Author(s):  
Irina V. Balyasnikova ◽  
Zenda L. Woodman ◽  
Ronald F. Albrecht ◽  
Ramanathan Natesh ◽  
K. Ravi Acharya ◽  
...  

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Sally Badawi ◽  
Bassam R. Ali

AbstractWith the emergence of the novel coronavirus SARS-CoV-2 since December 2019, more than 65 million cases have been reported worldwide. This virus has shown high infectivity and severe symptoms in some cases, leading to over 1.5 million deaths globally. Despite the collaborative and concerted research efforts that have been made, no effective medication for COVID-19 (coronavirus disease-2019) is currently available. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as an initial mediator for viral attachment and host cell invasion. ACE2 is widely distributed in the human tissues including the cell surface of lung cells which represent the primary site of the infection. Inhibiting or reducing cell surface availability of ACE2 represents a promising therapy for tackling COVID-19. In this context, most ACE2–based therapeutic strategies have aimed to tackle the virus through the use of angiotensin-converting enzyme (ACE) inhibitors or neutralizing the virus by exogenous administration of ACE2, which does not directly aim to reduce its membrane availability. However, through this review, we present a different perspective focusing on the subcellular localization and trafficking of ACE2. Membrane targeting of ACE2, and shedding and cellular trafficking pathways including the internalization are not well elucidated in literature. Therefore, we hereby present an overview of the fate of newly synthesized ACE2, its post translational modifications, and what is known of its trafficking pathways. In addition, we highlight the possibility that some of the identified ACE2 missense variants might affect its trafficking efficiency and localization and hence may explain some of the observed variable severity of SARS-CoV-2 infections. Moreover, an extensive understanding of these processes is necessarily required to evaluate the potential use of ACE2 as a credible therapeutic target.


Author(s):  
Vishal Madanlal Chaudhari ◽  
Dnyanoba Kishanrao Bhaskar ◽  
Medha Ajit Oak

The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining hemodynamic stability and thereby impacts multiple organ systems, such as the central nervous system, heart, and kidneys. Angiotensin II (ang II) is the main effector of the RAAS. However, overactivity of the RAAS can give rise to cardiovascular disorders, stroke, and nephrosclerosis. Unfavorable effects on cardiovascular system are attributed to ang II. RAAS activation also results in release and increased activity of several hormonal and inflammatory mediators, trigger formation of a number of secondary messengers and/or activate pathways, which negatively affects blood vessels and tissue. RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and calcium channel blockers can protect various organs from damage by blocking the protean manifestation of RAAS activity, either in its circulating or its locally tissue-active form. This review explains on the pleiotropic effects and benefits that go beyond mere blood pressure control. ACEIs in terms of mortality reduction, long‑term survival benefits, cardioprotective and vasculo-protective effects as well as improve fibrinolytic balance. Ramipril has been clinically proven to reduce rates of mortality, myocardial infarction, and stroke. ACEIs and ARBs were associated with lesser risks of COVID-19 infection.


2004 ◽  
Vol 271 (12) ◽  
pp. 2539-2547 ◽  
Author(s):  
Tobias M. J. Allinson ◽  
Edward T. Parkin ◽  
Thomas P. Condon ◽  
Sylva L. U. Schwager ◽  
Edward D. Sturrock ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document